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lopharingytis, acute exacerbation of chronic bronchitis
(AECB) and community acquired pneumonia (CAP).
METHODS: A decision-tree model was build to calculate
the cost-effectiveness of the comparators in 2 cohorts of
1000 patients with each condition with a time horizon of
2 months. The study was conducted from the perspective
of the Spanish NHS but an alternative scenario included
the productivity losses. Efﬁcacy rates were retrieved from
published randomized controlled clinical trials. Compli-
ance rates were retrieved from a published clinical study
that evaluated patient compliance to antibiotic therapy
with OD, BD and three times daily dosing. Health care
resource use in each condition was retrieved from a 
panel of 9 experts. The unit costs of resources were
obtained from national databases (€2003). The results 
of the study were expressed in terms of incremental 
cost-effectiveness ratio (ICER) per patient experiencing
improvement or cure. RESULTS: The incremental effec-
tiveness of the OD regime vs. BD regime is 10%, 14%
and 16%, in tonsillopharingytis, AEBC and CAP, respec-
tively. The ICER was €13 in tonsillopharingytis. In AEBC
and CAP, CL OD is the dominant treatment strategy,
offering higher effectiveness at lower costs. The scenario
including productivity losses shows that the treatment
with CL OD becomes less costly than CL BD in the three
conditions ranging from -7 euros (tonsillopharingytis) 
to -€158 (CAP) per patient treated. CONCLUSIONS:
Higher compliance rates with CL OD vs. CL BD increase
treatment effectiveness and improve the efﬁciency of the
OD antibiotic treatment. Considering productivity losses,
CL OD is a cost-saving option in all conditions under
analysis.
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OBJECTIVES: Worldwide, a large burden of invasive
bacterial infections in infants is caused by meningococcal
B, C and pneumococcal infections. In this presentation,
the potential impact of a neonatal program with a newly
developed combination vaccine in the Netherlands is
analysed. METHODS: A decision analysis framework
was developed using epidemiological and health care
resource use data from 1996–2001. This model is used to
estimate costs, beneﬁts, and health gains associated with
vaccinating all newborns. In the resulting cost-
effectiveness analysis, the societal perspective is taken.
RESULTS: Annually, on average 663 cases of invasive
pneumococcal and meningococcal B and C infection
occur in infants aged 0 to 10 years. Introduction of the
combination vaccine would prevent 233 cases of menin-
gitis and 115 cases of bacteremia per year. Additionally,
3020 cases of pneumococcal pneumonia and 38,870 cases
of otitis media would be prevented. Vaccination saves 34
lives per year and prevents 69 cases of severe sequelae.
This translates into 845 life years gained, or 999 quality
adjusted life years gained. Next to these health gains, 
vaccination will prevent €18,310,882 of the direct and
indirect medical costs due to meningococcal and 
pneumococcal infections in the Netherlands. Base case
cost-effectiveness (vaccine price €40) is €17,951 per
QALY. The model is most sensitive to changes in inci-
dence, vaccine price, and duration of protective efﬁcacy.
CONCLUSIONS: The introduction of this vaccine for
infants leadS to large reductions in morbidity and mor-




TREATMENT STRATEGIES WITH INTRAPARTUM
ANTIBIOTIC PROPHYLAXIS TO PREVENT
EARLY-ONSET GROUP B STREPTOCOCCAL
DISEASE
van den Akker E, Rijnders M, van Dommelen P
TNO Preventie en Gezondheid, Leiden, Zuid Holland,
Netherlands
OBJECTIVE: To estimate the costs and effects of differ-
ent treatment strategies with intrapartum antibiotic pro-
phylaxis to prevent early-onset group B streptococcal
disease in the Netherlands. The treatment strategies
include a risk-based strategy, a screening based strategy,
a combined screening/risk based strategy, and the current
Dutch guideline. METHODS: A decision analysis model
was used to compare the costs and effects of different
treatment strategies with no treatment for a hypothetical
cohort of 200,000 neonates. Baseline estimates were
derived from literature and a survey among parents of
GBS children. The analysis was performed from a soci-
etal perspective, and costs and effects were discounted at
a percentage of 3%. RESULTS: The introduction of 
a combined screening/risk-based strategy with universal
screening in pregnancy providing intrapartum prophy-
laxis for women with a risk factor or for unscreened
women with pre-term labor would prevent 362 of the 600
cases with early-onset GBS for €9200 per QALY gained.
The risk-based strategy is also an efﬁcient strategy pre-
venting 379 cases of onset GBS and a cost-effectiveness
ratio of €10,200 per QALY gained. The other strategies
resulted in lower effects for higher costs. Introducing 
the PCR test does not lead to more favorable cost-
effectiveness ratios. CONCLUSIONS: In the Dutch
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system the combined screening/risk-based strategy and
the risk-based strategy are efﬁcient strategies with rea-
sonable cost-effectiveness.
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OBJECTIVES: To evaluate two screening programs for
Chlamydia Trachomatis (CT) in France by measuring cost
per case and cost per treated case. METHODS: We eval-
uated the cost-effectiveness ratios of two CT screening
strategies using a decision tree model. Strategy A involved
screening of asymptomatic women only with partner
notiﬁcation; Strategy B involved screening of both asymp-
tomatic men and women with partner notiﬁcation. The
current strategy of no screening was not evaluated. Clin-
ical pathways were validated by a panel of experts. Direct
cost analysis was performed from the point of view of the
French National Health Insurance System. RESULTS:
Overall, 347 women, and their partners could be treated
by strategy A, and 296 individuals and their partners by
strategy B. The total cost of strategy B was lower than
that of strategy A (€213,400 compared to €250,558).
Costs per case and costs per treated case were compara-
ble for the two strategies, €557 and €722 respectively.
According to a sensitivity analysis, the key variables were:
CT prevalence, male participation rate, and likelihood
that a man should consult a doctor. CONCLUSIONS:
This is the ﬁrst model for CT screening built on French
data and thus a useful tool for French health policy deci-
sion-makers as it provides estimates for budgetary impact
analysis. Its limitations are the hypotheses on which it is
based (averted outcomes, direct costs . . .). Besides com-
paring the cost-effectiveness of screening, our study high-
lighted the need to standardize clinical practice and
develop a good communication program.
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OBJECTIVES: To estimate the incremental cost-
effectiveness ratio (ICER) of routine meningococcal
serogroup C conjugate vaccination of children at 2, 3,
and 4, or at 5 and 6 months instead of at 14 months in
the Netherlands and to determine the impact of includ-
ing herd-immunity. METHODS: The analysis was per-
formed from a societal perspective and in accordance to
the Dutch guidelines for pharmacoeconomic research,
using a cohort model. Direct and indirect (friction cost
method) costs were considered. Future costs and effects
were discounted at 4% and 2000 was chosen as baseline
year. A vaccine effectiveness of 90% (based on UK data)
and a vaccine protection duration of 20 years (based on
the experience with Haemophilus inﬂuenzae type b) were
used. Also on the basis of UK data, we assumed that 70%
of all unvaccinated persons aged 0–14 months are pro-
tected because of the herd-immunity effect caused by 
the recent meningococcal C conjugate vaccination of all
persons aged 14 months to 18 years. RESULTS: For
immunization of children at 2, 3, and 4 (5 + 6) months,
the herd-immunity effect decreases the yearly number of
additional life years gained from 51 (36) to 15 (11) but
leads to a strong increase of the ICER from €149,000
(€105,000) per life year gained to €497,000 (€349,000)
per life year gained. Even if only a herd-immunity effect
of 50% is assumed, the ICER still increases to about
€298,000 (€209,000) per life year gained. These results
are sensitive to the protection duration and effectiveness
of the vaccine and the meningococcal C incidence. CON-
CLUSIONS: The inclusion of herd-immunity decreases
the rendered small health gain and thus leads to even less
favorable cost-effectiveness ratios for vaccination of chil-
dren aged less than one year. Hence, the current Dutch
vaccination strategy of routine vaccinating children at 14
months should not be changed.
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Respiratory syncytial virus (RSV) is a leading cause of a
lower respiratory tract infection in infants and is respon-
sible for increased hospitalization, morbidity, and deaths
amongst high-risk individuals including those who are
born prematurely. As the treatment of RSV infections is
limited the analysis was focused on prophylactic therapy
with palivizumab, a humanized murine monoclonal anti-
body that provides passive immunity against RSV.
OBJECTIVES: To evaluate costs and cost-effectiveness of
RSV prophylaxis among infants born at less than 32
weeks gestation in Poland. METHODS: Decision tree
analysis was used to compare cost-effectiveness of two
strategies, palivizumab and no prophylaxis, among a
hypothetical cohort of infants born <32 gestational age.
Probabilities were derived from published trials. Costs
encompassed: drug costs, costs of non-intensive and
intensive pediatric hospital care and costs of asthma treat-
ment up to age 7. The discount rate of costs was set at
